A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma

TY - JOUR

T1 - A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma

AU - Ramasamy, Karthik

AU - Nooka, Ajay

AU - Quach, Hang

AU - Htut, Myo

AU - Popat, Rakesh

AU - Liedtke, Michaela

AU - Tuchman, Sascha A.

AU - Laubach, Jacob

AU - Gasparetto, Cristina

AU - Chanan-Khan, Asher

AU - Hertzberg, Mark

AU - deMario, Mark

AU - Nueesch, Eveline

AU - Chesne, Evelyne

AU - Franjkovic, Izolda

AU - Lechner, Katharina

AU - Kornacker, Martin

AU - Cho, Hearn Jay

N1 - Funding Information: This study was funded by F. Hoffmann-La Roche Ltd. We are grateful to the patients and their families, and the study team at the participating centers. We thank XYZ. We also thank Fiona Russel-Yarde and Christian Seitz, Medical Writers funded by F. Hoffmann-La Roche Ltd, for supporting the generation of the initial draft and for editorial help with adapting the letter to journal guidelines, respectively. Funding Information: K.R.: Janssen: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding, Speakers Bureau; BMS: Consultancy, Research Funding, Speakers Bureau; Takeda: Consultancy, Research Funding, Speakers Bureau; Amgen: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; Oncopeptides: Consultancy, Honoraria. A.N.: Adaptive Technologies: Consultancy, Honoraria; Oncopeptides: Consultancy, Honoraria; Spectrum Pharmaceuticals: Consultancy; GlaxoSmithKline: Consultancy, Honoraria, Other: Personal Fees: Travel/accommodations/expenses, Research Funding; Takeda: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Bristol Myers Squibb: Consultancy, Honoraria, Research Funding; Sanofi: Consultancy, Honoraria; Karyopharm Therapeutics, Adaptive technologies: Consultancy, Honoraria, Research Funding. H.Q.: Amgen, Celgene, Karyopharm, GSK, Janssen Cilag, Sanofi.: Membership on an entity’s Board of Directors or advisory committees; GlaxoSmithKline, Karyopharm, Amgen, Celgene, Janssen Cilag: Consultancy; GlaxoSmithKline, Karyopharm, Amgen, Celgene, Janssen Cilag: Honoraria; Amgen, Sanofi, Celgene, Karyopharm, GSK: Research Funding. M.H.: City of Hope Medical Center: Current Employment. R.P.: AbbVie: Consultancy, Honoraria; Celgene: Consultancy, Honoraria; Takeda: Consultancy, Honoraria, Other: Travel support, Research Funding; Bristol Myers Squibb: Consultancy, Honoraria; GSK: Consultancy, Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company); Janssen: Consultancy, Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company). M.L.: Jazz Pharmaceuticals: Membership on an entity’s Board of Directors or advisory committees; GSK: Membership on an entity’s Board of Directors or advisory committees; Pfizer: Honoraria; Janssen: Membership on an entity’s Board of Directors or advisory committees; Celgene: Membership on an entity’s Board of Directors or advisory committees; Caelum: Membership on an entity’s Board of Directors or advisory committees; Adaptive: Membership on an entity’s Board of Directors or advisory committees. S.A.T.: Caelum: Honoraria; Sanofi: Honoraria, Research Funding; Amgen: Research Funding; Janssen: Research Funding; Oncopep-tides: Consultancy; Roche: Research Funding; Karyopharm: Honoraria, Research Funding; Celgene: Honoraria, Research Funding, Speakers Bureau. J.L.: nothing to disclose. C.G.: nothing to disclose. A.C.-K.: nothing to disclose. M.H.: Gilead: Membership on an entity’s Board of Directors or advisory committees; MSD: Membership on an entity’s Board of Directors or advisory committees; Abbvie: Honoraria; BMS: Honoraria; Takeda: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Roche: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Other: Support of parent study and funding of editorial support. M.d.M.: BioNTech SE: Current Employment, Current equity holder in the publicly-traded company; Hoffmann-La Roche Ltd.: Current equity holder in a publicly-traded company, Ended employment in the past 24 months. E.N.: Hoffmann-La Roche Ltd.: Current Employment, Current equity holder in the publicly-traded company. E.C.: Hoffmann-La Roche Ltd.: Current Employment, Current equity holder in the publicly-traded company. I.F.: Hoffmann-La Roche Ltd.: Current Employment, Current equity holder in the publicly-traded company. K.L.: Roche Diagnostics GmbH: Current Employment, Current equity holder in the publicly-traded company. M.K.: Hoffmann-La Roche Ltd.: Current Employment, Current equity holder in the publicly-traded company. H.J.C.: Paid employee of the MMRF; research funding from Takeda, Celgene, and Genentech.

PY - 2021/9

Y1 - 2021/9

UR - http://www.scopus.com/inward/record.url?scp=85114631327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85114631327&partnerID=8YFLogxK

U2 - 10.1038/s41408-021-00545-w

DO - 10.1038/s41408-021-00545-w

M3 - Letter

C2 - 34480019

AN - SCOPUS:85114631327

SN - 2044-5385

VL - 11

JO - Blood cancer journal

JF - Blood cancer journal

IS - 9

M1 - 149

ER -